Recursion Pharmaceuticals

Overview

Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical-stage biotechnology company leveraging AI and high-throughput automated experimentation to accelerate drug discovery across multiple therapeutic areas, including oncology, neuroscience, and rare diseases["@recursion"].

Company Profile

| Attribute | Details |
|-----------|---------|
| Headquarters | Salt Lake City, Utah, USA |
| Founded | 2013 |
| CEO | Chris Gibson (Co-founder) |
| Market Cap | ~$500M-$2B (varies) |
| Employees | ~600 |
| Stock Symbol | RXRX (NASDAQ) |

History & Milestones

Overview

Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical-stage biotechnology company leveraging AI and high-throughput automated experimentation to accelerate drug discovery across multiple therapeutic areas, including oncology, neuroscience, and rare diseases["@recursion"].

Company Profile

| Attribute | Details |
|-----------|---------|
| Headquarters | Salt Lake City, Utah, USA |
| Founded | 2013 |
| CEO | Chris Gibson (Co-founder) |
| Market Cap | ~$500M-$2B (varies) |
| Employees | ~600 |
| Stock Symbol | RXRX (NASDAQ) |

History & Milestones

• 2013: Founded in Salt Lake City, Utah
• 2019: Entered partnership with Roche/Genentech for AI-driven drug discovery
• 2021: IPO on NASDAQ (RXRX)
• 2022: Expanded into neuroscience with focus on neurodegenerative diseases
• 2023: Advanced multiple oncology candidates into clinical trials
• 2024: Continued expansion of CNS pipeline with new partnerships

AI & Technology Platform

Recursion's proprietary platform combines multiple cutting-edge technologies:

Core Technologies

• Machine Learning & Neural Networks: Advanced algorithms for predicting drug-target interactions, toxicity prediction, and pharmacokinetic modeling
• High-Throughput Automated Screening: State-of-the-art automated laboratories capable of testing millions of compounds in cell-based assays
• Phenotypic Screening: Cell-based assays to identify disease-relevant phenotypes without requiring known molecular targets
• Bioinformatics Integration: Large-scale genomic and transcriptomic data integration for target identification
• Digital Biology: Cell painting and morphological profiling to understand drug effects at the cellular level

Automated Lab Infrastructure

Recursion operates one of the largest automated drug discovery laboratories in the industry, featuring:

• Robotic compound handling
• Automated cell culture systems
• High-content imaging
• Integrated data pipelines

Neuroscience Pipeline

Recursion has established a significant presence in neuroscience with multiple programs targeting neurodegenerative diseases:

Alzheimer's Disease Programs

| Program | Target | Stage | Mechanism |
|---------|--------|-------|-----------|
| REC-994 | Amyloid/Tau | Preclinical | Disease-modifying |
| REC-4881 | Neuroinflammation | Preclinical | Anti-inflammatory |

Parkinson's Disease Programs

| Program | Target | Stage | Mechanism |
|---------|--------|-------|-----------|
| REC-4881 | [Alpha-synuclein](/proteins/alpha-synuclein) | Preclinical | Protein aggregation modulation |
| TBA | [LRRK2](/entities/lrrk2) | Discovery | Kinase inhibition |

Additional CNS Programs

• Collaboration with Roche/Genentech: Multi-year partnership for AI-driven target identification in CNS disorders
• Neuroinflammation: Programs targeting microglial activation and neuroinflammation in AD and PD
• ALS and Huntington's: Preclinical programs for other neurodegenerative conditions
• Neurodegeneration Focus: Emphasis on protein aggregation, mitochondrial dysfunction, and neuroinflammation

Target Classes

• [Protein aggregation inhibitors](/therapeutics/protein-aggregation-inhibitors)
• [Neuroinflammation](/mechanisms/neuroinflammation) modulators
• [Mitochondrial](/mechanisms/mitochondrial-dysfunction) function enhancers
• Synaptic plasticity protectors

Partnerships & Collaborations

Major Pharmaceutical Partnerships

| Partner | Focus Area | Year | Status |
|---------|------------|------|--------|
| Roche/Genentech | AI-driven drug discovery | 2019 | Active |
| Takeda | Oncology | 2020 | Active |
| Biogen | Neuroscience | 2022 | Active |

Academic Collaborations

• Multiple academic partnerships for target validation
• University of Utah research collaboration
• Partnerships with leading neuroscience research centers

Clinical Development Strategy

Recursion's approach to clinical development includes:

• Biomarker-driven patient selection
• Precision medicine approaches
• Adaptive trial designs
• Digital health integration

Financial Overview

Stock Performance

• IPO Date: February 2021
• Exchange: NASDAQ
• Symbol: RXRX

Funding History

• Series A-C: $200M+ raised prior to IPO
• IPO Proceeds: ~$400M
• Post-IPO: Strategic investments and partnerships

Competitive Landscape

Recursion competes with other AI-driven drug discovery companies including:

• Exscientia
• Insilico Medicine
• Atomwise
• Relay Therapeutics

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [AI in Drug Discovery](/technologies/ai-drug-discovery)
• [Roche](/companies/roche)
• [Biogen](/companies/biogen)

External Links

• [Recursion Pharmaceuticals Website](https://recursion.com/)
• [NASDAQ: RXRX](https://www.nasdaq.com/market-activity/stocks/rxrx)
• [Clinical Trials](https://clinicaltrials.gov/)

References

[@recursiona]: [Recursion Pharmaceuticals SEC Filings](https://investor.recursion.com/)
[@roche]: [Roche Partnership Announcement](https://www.businesswire.com/)